Evidence map›Paper›PMID 34504494›Full record

ArticleFrontiers in immunology2021

Case Report: Complete Response of Primary Massive Hepatocellular Carcinoma to Anti-Programmed Death Ligand-1 Antibody Following Progression on Anti-Programmed Death-1 Antibody.

Gang Liu, Wenxuan Zhou, Xiaoli Li, Lijie Guo, Tingting He, Juan Zhao, Liansheng Gong

Open access · goldAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in immunology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.7field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 9 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Evolving therapeutic landscape of advanced hepatocellular carcinoma.Nature reviews. Gastroenterology & hepatology · 2023
    Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Gang LiuDepartment of Biliary Surgery, Xiangya Hospital, Central South University, Changsha, China.
Wenxuan ZhouDepartment of Biliary Surgery, Xiangya Hospital, Central South University, Changsha, China.
Xiaoli LiDepartment of Biliary Surgery, Xiangya Hospital, Central South University, Changsha, China.
Lijie GuoMedical Affair Department, OrigiMed, Shanghai, China.
Tingting HeMedical Affair Department, OrigiMed, Shanghai, China.
Juan ZhaoMedical Affair Department, OrigiMed, Shanghai, China.
Liansheng GongDepartment of Biliary Surgery, Xiangya Hospital, Central South University, Changsha, China.
Unimed Medical Institute · CNXiangya Hospital Central South University · CNCentral South University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Hepatocellular carcinoma (HCC) is an aggressive liver tumor that occurs due to chronic liver disease, and it has a high mortality rate and limited treatment options. Immune checkpoint inhibitors have been successfully introduced and used in cancer therapy, among which inhibitors of programmed death ligand-1 (PD-L1) and its receptor programmed death-1 (PD-1) are commonly administered for HCC as combination therapy, including combined anti-angiogenic and immunotherapy combination therapy. We report a case of a primary massive HCC patient with portal hepatic vein tumor thrombus who had a good response to atezolizumab in combination with bevacizumab, following progression of disease on combined immunotherapy with pembrolizumab and lenvatinib. This case demonstrates for the first time that an HCC patient who is resistant to anti-PD-1 antibody immunotherapy can benefit from anti-PD-L1 antibody immunotherapy, providing a potentially promising strategy for the treatment of HCC.

Indexed as

Angiogenesis InhibitorsAntibodies, Monoclonal, HumanizedAntineoplastic Combined Chemotherapy ProtocolsB7-H1 AntigenBevacizumabCarcinoma, HepatocellularDrug SubstitutionFemaleHepatitis B, ChronicHumansImmune Checkpoint InhibitorsLiver CirrhosisLiver NeoplasmsMiddle AgedPhenylurea CompoundsPortal VeinAngiogenesis InhibitorsAntibodies, Monoclonal, HumanizedatezolizumabB7-H1 AntigenBevacizumabCD274 protein, humanImmune Checkpoint InhibitorslenvatinibPDCD1 protein, humanpembrolizumabPhenylurea CompoundsProgrammed Cell Death 1 ReceptorQuinolinesatezolizumabHCCimmunotherapyPD-1PD-L1pembrolizumab

Identifiers

PMID34504494
PMCPMC8422947
OpenAlexW3195664255

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.